PubHawk
J Transl Med June 2023 PMID 37322482

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.

Michael Kurnellas, Ananya Mitra, Tina Schwabe, Robert Paul, Andrew E Arrant, Erik D Roberson, Michael Ward, Felix Yeh, Hua Long, Arnon Rosenthal

Full text PDF Download social card

Mentions

15
Peak: 9 in Jun 2023
across 3 sources since Jun 2023

Extended reach

45,226
potential audience

Total likes

16

Video views

114

Mentions per month

Jun 2023 – Dec 2024

Where it's discussed

  • X / Twitter11 posts
  • News3 articles
  • YouTube1 videos

AI synopsis

What people are saying

The discussions demonstrate strong interest in the therapeutic potential of latozinemab, with phrases like 'neat way of stopping dementia' and mentions of ongoing clinical trials, highlighting optimism and curiosity. The tone is positive and engaged, emphasizing research details and broader disease implications, which supports the moderate impact score.

AgreementModerate agreement

Most discussions acknowledge the potential of latozinemab as a promising treatment, reinforcing the article's optimistic outlook.

InterestHigh interest

The discussions show high interest, with mentions of clinical trials, mechanisms, and broader neurodegenerative implications.

EngagementModerate engagement

Postings include references to mechanisms, ongoing trials, and related research, indicating thoughtful engagement.

ImpactModerate impact

The focus on the development, targeting, and potential therapeutic applications suggests a moderate to high perceived impact.

Abstract in brief

  • Latozinemab is a new human monoclonal antibody designed to increase levels of progranulin (PGRN), a protein whose deficiency is linked to frontotemporal dementia (FTD) caused by mutations in the PGRN gene.
  • The drug works by lowering sortilin, a receptor that directs PGRN to lysosomes for degradation, thus increasing PGRN levels in the body, demonstrated in both animal studies and initial human clinical trials.
  • These findings suggest latozinemab could be a promising treatment for FTD and potentially other neurodegenerative diseases, with ongoing clinical trials to further evaluate its safety and effectiveness.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Dr. Thomas Ichim
@exosome · X

Really neat way of stopping dementia....an antibody the prevents breakdown of progranulin https://t.co/lWGKeA6Zi6

Jul 11, 2023 · 7 likes · 33,026 followers View post →
Bluefield Project
@BluefieldProj · X

New publication from @AlectorTx & @RobersonLabUAB describing MoA & target engagement for #Latozinemab (AL001), now in Ph3 trials for #GRN-FTD. Blocking the sortilin-PGRN interaction Grn+/- mice rescued the hets' social dominance phenotype in tube test. https://t.co/proJYI1TDB

Jun 19, 2023 · 6 likes · 3 shares · 899 followers View post →
TheForestnottheTrees
@richtrades100 · X

as well as in other neurodegenerative diseases where genetic mutations reduce PGRN levels, such as Parkinson’s disease [34, 35], Alzheimer’s disease [36], amyotrophic lateral sclerosis [37, 38], and limbic-predominant age-related TDP-43 encephalopathy https://t.co/Jqm4RUMPpX

Dec 28, 2024 · 2 likes · 4,436 followers View post →
Alector
@AlectorTx · X

Recently, @BioMedCentral's Journal of Translational Medicine released a publication detailing the development of an Alector investigational product for those suffering from #FTD. Thank you to Alectorians for their commitment to moving our program forward. https://t.co/OvgS2SnMj3 https://t.co/W83TdX85qW

Jun 20, 2023 · 1 like · 1 share · 285 followers View post →
Jordi A Matias-Guiu
@MatiasGuiu · X

RT @AlectorTx: Recently, @BioMedCentral's Journal of Translational Medicine released a publication detailing the development of an Alector…

Jun 20, 2023 · 1 share · 2,967 followers View post →
Rothstein Lab
@Rothstein_Lab · X

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia https://t.co/iPW8gmA9St

Jun 20, 2023 · 1,292 followers View post →

All mentions

TheForestnottheTrees
@richtrades100 · X

as well as in other neurodegenerative diseases where genetic mutations reduce PGRN levels, such as Parkinson’s disease [34, 35], Alzheimer’s disease [36], amyotrophic lateral sclerosis [37, 38], and limbic-predominant age-related TDP-43 encephalopathy https://t.co/Jqm4RUMPpX

Dec 28, 2024 · 2 likes · 4,436 followers View post →
Dr. Thomas Ichim
@exosome · X

Really neat way of stopping dementia....an antibody the prevents breakdown of progranulin https://t.co/lWGKeA6Zi6

Jul 11, 2023 · 7 likes · 33,026 followers View post →
Lala
@CNSProteostasis · X

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia https://t.co/mfeo1f0hMI https://t.co/vHJ3syeGNz

Jun 23, 2023 · 20 followers View post →
Rothstein Lab
@Rothstein_Lab · X

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia https://t.co/iPW8gmA9St

Jun 20, 2023 · 1,292 followers View post →
Rothstein Lab
@Rothstein_Lab · X

RT @BluefieldProj: New publication from @AlectorTx & @RobersonLabUAB describing MoA & target engagement for #Latozinemab (AL001), now in Ph…

Jun 20, 2023 · 3 shares · 1,292 followers View post →
Belle Yu
@inBelleYuAble · X

RT @BluefieldProj: New publication from @AlectorTx & @RobersonLabUAB describing MoA & target engagement for #Latozinemab (AL001), now in Ph…

Jun 20, 2023 · 3 shares · 121 followers View post →
Jordi A Matias-Guiu
@MatiasGuiu · X

RT @AlectorTx: Recently, @BioMedCentral's Journal of Translational Medicine released a publication detailing the development of an Alector…

Jun 20, 2023 · 1 share · 2,967 followers View post →
Alector
@AlectorTx · X

Recently, @BioMedCentral's Journal of Translational Medicine released a publication detailing the development of an Alector investigational product for those suffering from #FTD. Thank you to Alectorians for their commitment to moving our program forward. https://t.co/OvgS2SnMj3 https://t.co/W83TdX85qW

Jun 20, 2023 · 1 like · 1 share · 285 followers View post →
Erik Roberson
@RobersonLabUAB · X

RT @BluefieldProj: New publication from @AlectorTx & @RobersonLabUAB describing MoA & target engagement for #Latozinemab (AL001), now in Ph…

Jun 20, 2023 · 3 shares · 435 followers View post →
Bluefield Project
@BluefieldProj · X

New publication from @AlectorTx & @RobersonLabUAB describing MoA & target engagement for #Latozinemab (AL001), now in Ph3 trials for #GRN-FTD. Blocking the sortilin-PGRN interaction Grn+/- mice rescued the hets' social dominance phenotype in tube test. https://t.co/proJYI1TDB

Jun 19, 2023 · 6 likes · 3 shares · 899 followers View post →
MS Papers
@MltplSclppr · X

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia https://t.co/8e1zPbuQ1J

Jun 16, 2023 · 311 followers View post →